Atlas Trials

The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia.

Clinical trial NCT06674694 · RECRUITING

Trial details

NCT number
NCT06674694
Sponsor
Sichuan Kelun Pharmaceutical Co.,Ltd.
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Schizophrenia Disorders
Start date
2024-04-10
Primary completion
2026-06-30
Enrollment
56

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.